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Abstract	   Today	   enormous	   research	   efforts	   are	   focused	   on	   alleviating	   the	   massive,	   adverse	   effects	   of	   obesity.	   Short	  
peptides	   are	   key	   targets	   for	   research	   as	   they	   can	   be	   generated	   from	   natural	   proteins,	   like	   milk.	   Here	   we	   conducted	  
Trypsinogen	  digestion	  of	  Beta-­‐lactoglobulin	  (β-­‐Lg),	  the	  major	  mammalian	  milk	  protein,	  to	  release	  the	  hexamer	  VY6.	  It	  was	  
assayed	   in	   vivo	   for	   its	   activities	   on	   lipid	  metabolism	   using	   zebra	   fish	   as	   a	   vertebrate	  model.	   Zebra	   fish	   juveniles	   were	  
injected	   with	   two	   different	   doses	   of	   the	   peptide:	   100	   and	   800µg	   g-­‐1	   fish	   and	   left	   for	   5-­‐days	   before	   sacrificing.	   Lipids	  
measurements	   showed	   significant	   reduction	   in	   liver	   triglycerides	   and	   free	   cholesterol,	   as	   well	   as	   increased	   liver	   HDL	  
cholesterol.	  Dose-­‐dependent	   increases	  of	  mRNA	   levels	  of	   the	  genes	  coding	   for	   the	  enzymes	  acyl	   coenzyme	  A	  oxidase	  1	  
(acox1)	  and	  Lipoprotein	  lipase	  (lpl)	  were	  also	  found.	  The	  whole	  results	  suggest	  significant	  anti-­‐obesity	  activity	  of	  the	  β-­‐Lg-­‐
derived	  VY6	  peptide.	  Its	  use	  as	  a	  nutraceutical	  is	  discussed.	  
A. Introduction	  
	  
More	  than	  40	  million	  children	  under	  5	  years	  old	  and	  more	  than	  
1.4	   billion	   adults	   above	   20	   years	   old	   are	   suffering	   obesity1,2.	  
The	   dimension	   of	   the	   problem	   is	   enormous	   and	   researchers	  
and	   health	   agents	   are	   looking	   together	   for	   remedies	   to	  
prevent	   and	   control	   the	   pandemics.	   The	   search	   of	   food	  
components,	  preferably	  derived	  from	  natural	  products,	  able	  to	  
decrease	  metabolic	   lipid	   contents	   and	   controlling	   cholesterol	  
levels	  is	  therefore	  a	  priority.	  
Genetics	  has	  indeed	  a	  role	  in	  obesity.	  Among	  several	  enzymes	  
responsible	   for	   lipids	   catabolism,	   acyl-­‐coenzyme	   A	   oxidase	   1	  
(Acox1)	  and	   lipoprotein	   lipase	   (Lpl)	  are	  of	  special	   importance.	  
The	  product	  of	  the	  transcript	  acox1	  catabolizes	  both	  fatty	  acids	  
and	   reactive	   oxygen	   species	   (ROS)	   in	   the	   peroxisomal	   β-­‐
oxidation	   process.	   In	   liver	   and	   adipose	   tissues,	   it	   is	   the	   first	  
enzyme	   in	  such	  metabolic	  oxidation	  route3,4.	  Up-­‐regulation	  of	  
acox1	   gene	   expression	   is	   correlated	   with	   obesity-­‐inhibitory	  
treatments	   in	   the	   livers	  of	  different	  experimental	  models	  and	  
at	   different	   stages	   of	   life,	   starting	   very	   early	   in	   the	  
development5,6.	   Likewise,	   the	   enzyme	   produced	   by	   lpl	  
transcript	  is	  a	  potent	  controller	  of	  lipids,	  chiefly	  acting	  as	  rate-­‐
limiting	  enzyme	  for	  the	  hydrolysis	  of	  triglycerides	  and	  being	  a	  
potent	   anti-­‐hypertriglyceridemia	   molecule7.	   Therefore,	   any	  
food	  product	  able	   to	  activate	   these	   two	  genes	   is	  expected	   to	  
contribute	  to	  control	  obesity.	  
β-­‐lactoglobulin	   (β-­‐lg)	   is	   one	  of	   the	   chief	   proteins	   that	   remain	  
soluble	   within	   non-­‐skimmed	   or	   skimmed	   milk8.	   β-­‐lg-­‐derived	  
peptide	   VAGTWY	   (VY6)	   has	   already	   been	   assayed	   in	   vitro	   for	  
different	   biological	   activities,	   and	   exhibits	   anti-­‐diabetic9,	   anti-­‐
bacterial10,11,	  and	  ACE-­‐inhibitory	  and	  opioid-­‐like	  properties12,13.	  
However,	   to	   date	   no	   assays	   have	   been	   reported	   for	   anti-­‐
obesity	  properties,	  neither	   in	  vertebrate	  models.	  VY6	  showed	  
some	   glucose	   regulatory	   capability	   in	   mice14.	   However,	   they	  
administered	   whole	   β-­‐lg	   hydrolysates,	   not	   the	   purified	  
peptide.	  In	  fact,	  the	  utilization	  of	  zebra	  fish	  as	  an	  animal	  model	  
to	  assay	  the	  aforementioned	  peptide	  bioactivities	  constitutes	  a	  
novelty,	  since	  rats	  are	  normally	  the	  animal	  of	  choice15,16,17,18.	  
Zebra	   fish	   is	   an	  animal	  model	  of	   choice	   for	   studies	  of	  human	  
obesity	   because	   the	   metabolic	   routes	   that	   control	   the	  
processes	   conducing	   to	  obesity	   in	   zebra	   fish	   are	  quite	   similar	  
to	  the	  human’s19,20.	   In	  this	  study,	  VY6	  was	  obtained	  from	  β-­‐lg	  
by	   tryptic	   hydrolysis,	   and	   then	   isolated	   using	   a	   two-­‐step	  
process:	  ultrafiltration	  of	  the	  hydrolysate	  and	  semi-­‐preparative	  
RP-­‐HPLC	   fractionation	   of	   the	   permeate.	   It	   is	   important	   to	  
highlight	   that	   bioactivity	   assessments	   are	   usually	   performed	  
using	  synthetic	  peptides,	  rather	  than	  directly	  purified	  peptides	  
from	   the	   source	   of	   origin,	   as	   in	   the	   present	   case,	   as	  
synthesized	   peptides	   lack	   functional	   inhibitors	   or	   activity-­‐
modifiers	   deliberately	   added	   from	   the	  original	   protein	  during	  
the	   course	   of	   its	   purification	   for	   isolation	   of	   targeted	  
peptides21,22,23.	   VY6	   was	   subsequently	   assayed	   for	   its	   anti-­‐
obesity	  properties.	   In	  vivo	  assays	  were	  performed	  using	  zebra	  
fish	   (Danio	   rerio)	   as	   an	   animal	   model,	   focusing	   on	   lipid	  
contents	   and	   in	   the	   modification	   of	   the	   acox1	   and	   lpl	   gene	  
expression	  by	  reverse	  transcription-­‐polymerase	  chain	  reaction	  
(RT-­‐PCR)	  technique	  that	  is	  used	  in	  several	  studies	  dealing	  with	  
the	   effect	   of	   different	   nutraceuticals	   on	   physiological	  
performance	  in	  human	  and	  experimental	  animals24,25,26.	  
	  
B. 	  Materials	  and	  Methods	  
	  
B.1.	  Production	  of	  the	  peptide	  VY6	  
	  
The	  commercial	   substrate	  of	  Bovine	  β-­‐lg	   (supplied	  by	  Davisco	  
Foods	  International	  Inc.,	  Le	  Sueur,	  MN,	  USA)	  contained	  97.9	  %	  
protein	   (w/w)	   of	   which	   91.5	   %	   were	   β-­‐lg,	   according	   to	   the	  
manufacturer.	   Trypsin	   (T1426	   from	   bovine	   pancreas	   TPCK	  
treated,	   activity	   of	   ≥10000	   units/mg	   protein),	   acetonitrile	  
grade	   HPLC	   and	   TFA	  were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	  
Louis,	   MO,	   USA),	   VWR	   (Barcelona,	   Spain)	   and	   Panreac	  
(Barcelona,	   Spain),	   respectively.	   All	   other	   chemicals	   were	   of	  
analytical	  grade.	  
	   	  
	   	  
Bovine	  β-­‐lg	  solutions	  were	  prepared	  by	  solubilizing	  the	  protein	  
powder	  in3	  L	  of	  distilled	  water	  until	  a	  concentration	  of	  30	  g	  L-­‐1	  
was	   reached.	   The	   pH	   and	   temperature	   values	   were	   set	   to	   8	  
and	  37	  ºC	   respectively.	  Hydrolysis	  was	   carried	  out	   for	  23h	  by	  
adding	   trypsin	   at	   an	   enzyme:substrate	   ratio	   of	   1:450	   (w/w).	  
The	   pH	   was	   kept	   constant	   with	   a	   pH-­‐stat	   device	   model	   842	  
Titrando	   (Metrohm	   Ion	   Analysis,	   Herisau,	   Switzerland),	   that	  
added	   1M	   NaOH	   when	   necessary.	   Reaction	   was	   stopped	   by	  
lowering	  the	  pH	  with	  0.1	  M	  HCl,	  when	  the	  degree	  of	  hydrolysis	  
(DH)	  reached	  the	  target	  value	  of	  6.8	  %.	  The	  calculation	  of	  the	  
DH	  was	  based	  in	  the	  pH-­‐stat	  method27,	  using	  Eq.	  (1).	  
	  
DH % 	  =	  
B	  ·∙	  Nb
α	  ·∙	  MP	  ·∙	  hTOT
	  ×	  100	  
	   (1)	  
Where	  B	  (mL)	  is	  the	  volume	  of	  consumed	  base,	  NB	  (mol	  L
-­‐1)	  the	  
normality	  of	  the	  base,	  M	  (g)	  the	  mass	  of	  protein,	  hTOT	  the	  total	  
number	  of	  peptide	  bonds	   in	   the	   substrate	  protein.	  This	  value	  
was	   previously	   calculated	   by	   Cheison	   et	   al.	   (2010)28	   as	   7.2	  
meqv	   g-­‐1	   protein	   for	   β-­‐lg.α	   is	   the	   average	   degree	   of	  
dissociation	  of	  α-­‐amino	  groups	  in	  the	  hydrolysis	  system	  β-­‐lg	  +	  
Trypsin.	   In	   the	   present	   study,	   α	   was	   calculated	   according	   to	  
Camacho	  et	  al.	  (2001)29,	  and	  it	  took	  the	  value	  of	  0.979	  at	  pH	  8.	  
For	  the	  membrane	  permeation	  experiments,	   the	  hydrolysates	  
were	  first	  diluted	  in	  distilled	  water	  to	  a	  concentration	  of	  15	  g	  L-­‐
1.	  The	  membrane	  used	  for	   the	  fractionation	  process,	  made	  of	  
polyethersulfone	   (PES)	   with	   5	   kDa	   molecular	   weight	   cut	   off	  
(MWCO)	   and	   0.1	   m2	   filtration	   area	   (Millipore,	   Billerica,	   MA,	  
USA),was	   installed	  within	   a	   Pellicon	   2	  mini	   holder	   (Millipore,	  
Billerica,	   MA,	   USA).	   The	   filtration	   conditions	   were	   pH	   8,	  
temperature	   37	   ºC	   and	   transmembrane	   pressure	   (TMP)	  
7.5×105	   Pa.	   All	   membrane	   experiments	   were	   performed	   in	  
duplicate.	  
Peptides	   present	   in	   the	   permeate	   stream	   were	   further	  
separated	   by	   a	   Varian	   ProStarsemi-­‐preparative	   RP-­‐HPLC	  
(Varian,	  Palo	  Alto,	  CA,	  USA),	  equipped	  with	  a	  fraction	  collector.	  
Permeate	   samples	   were	   injected	   into	   a	   Dynamax	   Microsorb	  
300-­‐8	  C18	  (250×21.4	  mm,	  Varian,	  CA,	  USA)	  column,	  preceded	  
by	  a	  guard	  Dynamax	  Microsorb	  C18	  column	  (Varian,	  CA,	  USA).	  
The	  system	  was	  run	  at	  ambient	  temperature	  and	  a	  flow	  rate	  of	  
10	  mL	  min-­‐1,	   and	   light	   detection	   was	   set	   to	   214	   nm.	  Mobile	  
phase	   A	   was	   composed	   of	   0.1	   %	   TFA	   (v/v)	   in	   MilliQ	   water	  
(Millipore,	  Billerica,	  MA,	  USA)	   and	  mobile	  phase	  B	  was	  0.1	  %	  
TFA	   (v/v)	   in	   acetonitrile.	   The	   gradient	   was:	   5%	   B	   (0,1%	   TFA	  
(v/v)	  in	  acetonitrile)	  for	  8	  min,	  5	  to	  45	  %	  B	  in	  142	  min,	  45	  to	  80	  
%	   B	   in	   20	   min,	   80	   to	   95	   %	   B	   in	   5	   min	   and	   returning	   to	   the	  
starting	  conditions	  in	  1	  min.	  
The	   collected	   fractions	  were	  analysed	  with	  a	  Voyager-­‐DE	  STR	  
matrix	  assisted	   laser	  desorption/ionization	  time-­‐of-­‐flight	  mass	  
spectrometer	  (MALDI-­‐TOF/MS)	  (Applied	  Biosystems,	  Waltham,	  
MS,	   USA).	   Sample	   preparation	   was	   performed	   with	   Zip-­‐Tip	  
pipette	   tips	   containing	   C18	   reverse-­‐phase	   media	   (Millipore,	  
Billerica,	  MA,	  USA).	  A	  α-­‐cyano-­‐4-­‐hydroxy-­‐cinnamic	  acid	  (10mg	  
mL-­‐1	   in	   50	   %	   Acetonitrile-­‐0.1	   %	   TFA)	   (Sigma,	   St.	   Louis,	   MO,	  
USA)	  matrix	  was	  used.	  The	  MW	  range	  for	  the	  MS	  analysis	  was	  
from	   500	   to	   3500	   Da,	   and	   for	   external	   calibration	   a	  MSCAL2	  
calibration	   kit	   (Sigma,	   USA)	   was	   used.	   Mass	   spectrometry	  
acquisition	   was	   performed	   in	   reflectron	   mode	   and	   positive	  
polarity,	   with	   an	   acceleration	   voltage	   of	   25	   kV.	   The	   spectra	  
were	   processed	   with	   software	   Data	   Explorer	   (Applied	  
Biosystems,	   Waltham,	   MS,	   USA).	   Peptide	   identification	   was	  
carried	   out	   by	   MW,	   using	   the	   FindPept	   tool	   on	   the	   ExPASy	  
server	  (http://web.expasy.org/findpept/).	  
The	   fractions	   were	   further	   analysed	   by	   direct-­‐infusion	  
electrospray	  mass	  spectrometry	  (ESI-­‐MS/MS),	  so	  as	  to	  confirm	  
the	  correct	  identification	  of	  peptide,	  using	  a	  quadrupole	  time-­‐
of-­‐flight	   mass	   spectrometer	   equipped	   with	   an	   electrospray	  
source	  (Qstar	  XL,	  Applied	  Biosystems,	  Waltham,	  MS,	  USA).	  The	  
obtained	  MS/MS	  spectra	  were	  processed	  using	  Analyst	  QS	  1.1	  
(Applied	  Biosystems,	  Waltham,	  MS,	  USA).	  
The	  peptide	  of	   interest	   (VY6)	  was	  stored	  until	  zebra	  fish	  tests	  
using	  a	  Cryodos	  laboratory	  freeze-­‐dryer	  (Telstar	  Industrial,	  S.L.,	  
Terrassa,	  Barcelona,	  Spain).	  
	  
B.2.	   In	   vivo	   trial:	   zebra	   fish	   treatment,	   sampling	   and	  
measurements	  
	  
The	   experiments	   with	   living	   zebra	   fish	   followed	   the	   EU	  
standards	   for	   animal	   experiments	   and	  were	   approved	   by	   the	  
Committee	  of	   Ethics	  of	   the	  Asturias	  Principality	   as	   it	   is	   in	   the	  
Directive	  of	  the	  University	  of	  Oviedo	  of	  13	  of	  February	  of	  2014	  
(BOPA	  26/02/2014).	  	  
Juvenile	  zebra	  fish	  Danio	  rerio	  were	  purchased	  from	  ZF	  Biolabs	  
(Madrid,	   Spain),	  where	   they	  were	   raised	  under	   the	  minimum	  
levels	   of	   consanguinity.	   Fifteen	   fish	   were	   acclimated	   for	   14	  
days	   to	   normal,	   dechlorinated	   freshwater	   at	   ambient	  
temperature	   (22	   ºC)	   and	   normal	   summer	   light	   regime.	   They	  
were	   fed	  with	   standard	   fishmeal	   for	   tropical	   aquarium	   fishes	  
(Dajana	   Tropica	   Basic),	   containing	   7	   %	   crude	   oils	   and	   fat	  
materials,	  one	  dose	  a	  day	  as	  recommended.	  Despite	  being	  the	  
knowledge	  about	  the	  real	  requirements	  of	  nutrients	  lacking	  in	  
zebra	   fish	   and	   many	   other	   ornamental	   fishes,	   the	   need	   for	  
lipids	  should	  be	  adjusted	  since	  the	  low	  energy	  demands	  of	  the	  
fish	  make	  them	  prawn	  to	  fatty	  deposition30.	  The	  experimental	  
fish	   were	   divided	   at	   random	   in	   three	   groups	   of	   five	   fish	   of	  
similar	   weights,	   ranging	   between	   0.8796	   ±0.096	   and	   1.145±	  
0.19	   g.	   Two	  groups	  were	   treated	  with	   two	  different	  doses	  of	  
VY6,	  and	  the	  control	  group	  was	  treated	  with	  water.	  
Fish	  were	   anaesthetized	  using	   sublethal	   50	  mg	   L-­‐1	   of	   Ethyl	   3-­‐
aminobenzoate	   methanesulfonate	   (Tricaine,	   Santa	   Cruz	  
Biotechnology,	   Cat.	   no.	   10743661).	   Each	   fish	   was	  
intraperitoneally-­‐injected	   with	   10	   µL	   of	   one	   of	   the	   following	  
doses:	   low	   (20	   µg	   µL-­‐1:	   final	   in	   vivo	   injected	   dose=200	   µg	   g-­‐1	  
fish)	  or	  high	  (80	  µg	  µL-­‐1:	   final	   in	  vivo	   injected	  dose=800	  µg	  g-­‐1	  
fish)	  of	   the	  peptide.	   In	   the	   control	   group	   the	  Zebra	   fish	  were	  
injected	   with	   sterile	   water.	   For	   the	   injection	   10	   µL	   Hamilton	  
syringes	   were	   used	   (Hamilton®GASTIGHT®syringe,	   cemented	  
needle	   volume	   10	   μL,	   needle	   size	   26s	   Ga-­‐cone	   tip,	   Cat.	   no.	  
80039).	   After	   treatment	   the	   fish	   were	   kept	   in	   20	   L	   aquaria,	  
under	   normal	   environmental	   and	   feeding	   conditions,	   in	   a	  
closed-­‐recirculation	  water	  system	  with	  mechanical	  filters	  for	  7	  
days,	  renewing	  daily	  20	  %	  of	  tank	  waters.	  
For	   sampling,	   fish	   were	   anaesthetized	   by	   a	   lethal	   dose	   of	  
Tricaine	   (100	   mg	   L-­‐1).	   Each	   fish	   was	   dissected	   and	   the	   liver	  
removed.	  Twenty	  mg	  of	  the	  liver	  tissue	  were	  placed	  in	  RNAse-­‐
	  	   	  
free	   2	   mL	   Eppendorf	   tube	   and	   immediately	   flash	   frozen	   in	  
liquid	  nitrogen	  (N2,	  196	  ºC)	  for	  later	  total	  RNA	  extraction,	  and	  
the	  rest	  were	  kept	  in	  sterile	  2	  mL	  Eppendorf	  tube	  that	  was	  also	  
flash	   frozen	   in	   liquid	   N2for	   measurement	   of	   lipids.	   Both	  
aliquots	  were	  maintained	  at	  –80	  ºC	  until	  further	  analyses.	  
Total	   lipids	   were	   extracted	   from	   liver	   using	   the	   method	   of	  
Folch	   et	   al.	   (1957)31	   with	   slight	   modifications.	   In	   brief,	  
ultrafrozen	   livers	   (-­‐	   80	   ºC)	   were	   individually	   homogenized	   in	  
liquid	  N2,	  then	  resuspended	  with	  strong	  vortexing	  in	  500	  µL	  of	  
2:1	   chloroform:methanol	  mixture.	   The	   reconstituted	   samples	  
were	   centrifuged	   at	   10,000	   g	   for	   10	   min.	   The	   supernatants	  
were	  transferred	  to	  new	  1.5	  mL	  Eppendorf	  tubes,	  the	  process	  
of	   adding	   500	   µL	   of	   2:1	   chloroform:methanol	   was	   repeated	  
twice.	   Later	   on,	   100	   µL	   of	   0.9	   %	   NaCl	   were	   added	   to	   the	  
supernatant	   and	   the	   tubes	   were	   thoroughly	   vortexed	   for	  
strong	  mixing.	  The	  tubes	  were	  then	  centrifuged	  at	  4.000	  g	  for	  
30	   min.	   The	   lower	   layer	   containing	   lipids	   was	   collected	   to	   a	  
new	  1.5	  mL	  eppendorf	  tube	  that	  was	  incubated	  at	  37	  ºC	  for	  2	  
days	   for	   Chloroform:Methanol	   mixture	   evaporation.	   The	  
resulting	   lipids	   were	   reconstituted	   with	   250	   µL	   of	   10	   mM	  
KH2PO4	   a	   pH7,	   with	   strong	   vortex	   until	   complete	   lipids	  
dissolution.	   In	   these	   samples,	   triglycerides,	   free	   cholesterol,	  
and	   HDL	   cholesterol	   were	   measured	   using	   commercial	   kits	  
from	   Spinreact	   (Cat.	   no.	   1001310,	   41035,	   and	   10010196-­‐
respectively).	   KH2PO4	   (10	   mM,	   pH7)	   was	   used	   as	   negative	  
control.	   External	   standard	   curve	   method	   was	   used	   for	  
measurement	  of	  concentration	  in	  relation	  to	  the	  fluorescences	  
emitted	   by	   lipids	   standards	   prepared	   as	   five,	   half-­‐serial	  
dilutions	   from	   each	   major	   standard	   provided	   with	   the	   lipids	  
estimation	   kits.	   Extracted	   lipids	   samples	   and	   controls	   were	  
applied	   in	   duplicates	   in	   a	   96-­‐well	   microplate	   for	   each	  
treatment	   for	   measurement.	   Intra-­‐specific	   errors	   were	  
calculated	   as	   standard	   error	   of	   means	   of	   measurements	  
between	  the	  duplicates	  of	  the	  same	  sample.	  	  
	  
B.3.	   RNA	   extraction	   and	   reverse	   transcriptase	   polymerase	  
chain	  reaction	  (RT-­‐PCR)	  
Total	   liver	   RNA	   was	   extracted	   from	   each	   specimen	   using	  
GeneMATRIX	   Universal	   RNA	   Purification	   Kit	   (Eurx,	   Cat.	   no.	  
E3598)	   according	   to	   manufacturers´	   instructions,	  
reconstituting	  the	  tissue	  lysing	  buffer	  with	  2-­‐mercaptoethanol	  
(Sigma-­‐Aldrich,	  M3148-­‐250ML).	  Extreme	  caution	  was	  taken	  to	  
avoid	   introduction	   of	   RNAse	   into	   the	   working	   materials	   or	  
samples.	   All	   glass	  materials	   used	   for	   preparation	   of	   reagents	  
for	  RNA	  extraction	  were	  previously	  sterilized	  at	  180ºC	  for	  16	  h.	  
Working	   station,	   pipettes,	   centrifuges,	   and	   all	   other	   working	  
materials	  were	  thoroughly	  cleaned	  with	  absolute	  ethyl	  alcohol.	  
Diethylpyrocarbonate	   (DEPC,	   Merck,	   Cat.	   no.	   8.41751.0005)	  
was	   used	   for	   preparation	   of	   necessary	   dilutions	   of	   any	  
material.	  After	  RNA	  extraction,	  the	  quality	  of	  RNA	  was	  checked	  
using	   2	   %,	   RNase-­‐free	   agarose	   gel	   (UltraPure™	   Agarose,	  
LifeTechnologies,	   Cat.	   no.	   16500-­‐100),	   prepared	   with	   1X	   TBE	  
(Eurx,	   Cat.	   no.	   E0230-­‐01).	   1	   µL	   of	   RNA	   was	   loaded	   into	   the	  
agarose	   gel	   using	   RNase-­‐free	   gel-­‐loading	   buffer	  
(LifeTechnologies,	   Cat.	   no.	   AM8556.1).	   Success	   of	   extraction	  
was	   confirmed	   by	   the	   presence	   of	   2	   bands,	   of	   the	   28S	   rRNA	  
and	   the	   18S	   rRNA,	   with	   neither	   a	   smear	   or	   lower	   bands	   of	  
degradation,	  nor	  high	  molecular	  weight	  band	  of	  genomic	  DNA.	  
RNA	  quantity	  was	  determined	  through	  the	  spectrophotometric	  
measurement	   of	   absorbance	   at	   A260/280	   by	   BioPhotometer	  
Plus	   (Eppendorf).	   Samples	   with	   A260/280	   =	   1.8-­‐2	   were	  
considered	  adequate	  for	  cDNA	  synthesis.	  500	  ng	  of	  RNA	  from	  
each	   liver	   samples	   were	   used	   for	   synthesis	   of	   cDNA,	   using	  
EurxdART	  RT-­‐PCR	  kit	  (E0802-­‐01).	  
Semi-­‐quantitative	  RT-­‐PCR	  approach	  was	  used	  for	  assessing	  the	  
effects	  of	  the	  injected	  hexamer	  on	  two	  enzymes´	  genes	  related	  
to	  lipid	  degradation	  and	  oxidation	  in	  liver,	  that	  are	  Peroxisomal	  
acyl-­‐coenzyme	  A	  oxidase	  1	  (acox1)	  and	  Lipoprotein	  lipase	  (lpl).	  
The	   primers	   for	   acox1	   were:	   acox1Fw:	   5´-­‐
ACAGCAGAGCAAGAGTAACG-­‐3´	   and	   acox1Rv:	   5´-­‐
TGAAGGGCATAAAGCAGAGC-­‐3´.	   The	   primers	   for	   lpl	   were:	  
lplFw:	   5´-­‐CGCAGGAGCAGCAAGATG-­‐3´	   and	   lplRv:	   5´-­‐
GTTCAAAGTAGGCATAATGTAGGG	   -­‐3´.	   Beta	   actin	   (actb)	   was	  
used	   as	   reference	   gene	   as	   its	   expression	   does	   not	   change	  
under	   different	   chemical	   treatments	   to	   the	   zebra	   fish32.	   The	  
primers	   used	   for	   actb	   amplification	   in	   liver	   cDNA	   were	   β-­‐
actFw:	   5´-­‐CGAGCTGTCTTCCCATCCA-­‐3´	   and	   β-­‐actRv:	   5´-­‐
TCACCAACGTAGCTGTCTTTCTG-­‐3´33,34,35.	   All	   PCRs	   were	   carried	  
out	   using	   thermal	   cycler	   Applied	   Biosystems	   Model	   2720-­‐2.	  
The	  PCR	  mix	  contained	  in	  the	  previously	  mentioned	  RT-­‐PCR	  kit,	  
consisted	   of	   1x	   PCR	   buffer,	   0.2	   mM	   dNTPs,	   0.4	   mM	   of	   each	  
primer,	   and	   2.5	   units	   of	   Opti-­‐TaqDNA	   polymerase.	   The	   PCR	  
program	  consisted	  of	  an	   initial	  denaturation	  step	  at	  95	  ºC	   for	  
10	  min,	  then	  30	  cycles	  of	  95ºC	  for	  30	  s,	  50	  ºC	  for	  30	  s,	  and	  30	  s	  
at	  72	  ºC	   for	   the	  extension.	  The	  annealing	   temperature	   (50ºC)	  
was	   chosen	   according	   to	   preliminary	   optimization	   trials.	  
Finally,	  PCR	  products	  were	  visualized	  in	  2	  %	  agarose	  gel	  stained	  
by	   SimplySafe	   (Eurx,	   Cat.	   no.	   E4600-­‐01)	   nucleic	   acids	  
intercalating	   dye.	   The	   intensity	   of	   the	   resulting	   bands	   were	  
measured	   using	   the	   program	   ImageJ36.	   The	   values	   of	   each	  
band	  in	  the	  gel	  were	  normalized	  dividing	  the	  band	  intensity	  by	  
the	   intensity	   of	   the	  band	  of	   the	   reference	   gene	   (actb)	   of	   the	  
same	  sample. 
	  
B.4	  Statistical	  analyses	  
For	   all	   measurements,	   the	   results	   were	   analyzed	   using	   one-­‐
way	   ANOVA	   in	   the	   program	   Statgraphics	   Centurion	   IX.	   Tukey	  
HSD	  
was	  
used	   as	  
post-­‐









n	  groups	  of	  fish	  in	  pairwise	  tests.	  Differences	  were	  considered	  
significant	  at	  P<0.05.	  
	  
C. 	  Results	  
	   	  
	   	  
	  
C.1.	  VY6	  production	  
As	   stated	   in	   section	   B.1,	   the	   identity	   of	   the	   peptide	   was	  
confirmed	  by	  MALDI-­‐TOF/MS	  and	  MS/MS.	  Additionally,	   it	  was	  
characterised	   by	   RP-­‐HPLC	   so	   as	   to	   assess	   the	   purity	   of	   the	  
fraction.	   No	   additional	   peaks	   were	   found	   in	   the	  
chromatogram,	  as	  it	  can	  be	  seen	  in	  Figure	  1.	  The	  peptide	  was	  
characterized	   by	   a	   retention	   time	   (RT)	   of	   14.83	   min.	   The	  
National	   Center	   for	   Biotechnology	   Information	   (NCBI)	  
database	  was	  searched	  for	  the	  bovine	  β-­‐lg	  sequence,	  so	  as	  to	  
confirm	   that	  VY6	   sequence	  was	  within	   the	  protein	   sequence.	  












Fig.	   1:	   RP-­‐HPLC	   chromatographic	   profile	   of	   the	   semipreparative	   RP-­‐
HPLC	   isolated	   fraction	   identified	   as	   VY6	   by	   MALDI-­‐TOF/MS	   and	  
MS/MS.	  
	  
C.2.	  Effect	  of	  VY6	  on	  zebra	  fish	  hepatic	  lipids	  
	  
For	   all	   measurements,	   the	   ranges	   of	   linearity	   of	   standard	  
curves	   covered	   adequately	   the	   concentrations	   used.	   r2	   in	   all	  
cases	   ranged	   between	   0.999-­‐1.	   Moreover,	   very	   low	  
intraspecific	   error	   were	   found	   between	   duplicates	   of	   each	  
sample	   measure	   (1-­‐3	   x	   10-­‐3	   for	   triglycerides	   and	   free	  
cholesterol,	   and	   4-­‐5	   x	   10-­‐3	   for	   HDL)	   (see	   Table	   1).	   Peptide	  
injection	   induced	   significant	   reduction	   in	   the	   levels	   of	  
triglycerides	   in	   liver	  (one-­‐way	  ANOVA	  with	  F=	  75.35,	  P<0.001;	  
pairwise	  values	  in	  the	  Tukey’s	  test	  are	  all	  significant,	  see	  Table	  
2)	   The	   decrease	   was	   more	   intense	   in	   response	   to	   the	   lower	  
dose	   of	   the	   peptide	   injected	   (about	   one	   half	   of	   the	   control	  
level;	   Figure	   2),	   than	   with	   the	   high	   dose	   for	   which	   the	  
reduction	  of	  triglycerides	  was	  significant	   (comparison	  control-­‐
high	   dose	   with	   a	   p-­‐value	   of	   0.007;	   Table	   2).	   For	   the	   free	  
cholesterol	   the	   F-­‐value	   in	   a	   one-­‐way	   ANOVA	   was	   11.36	  
(P=0.009);	   however,	   the	   significant	   pairwise	   comparison	   was	  
between	   the	   groups	   treated	  with	   the	   high	   and	   the	   low	   dose	  
(Table	   2),	   but	   not	   with	   the	   control	   that	   was	   intermediate	  
between	  the	  two	  treated	  groups.	  A	  similar	  pattern	  was	  found	  
for	   HDL,	   with	   the	   low-­‐dose	   treatment	   exhibiting	   the	   lowest	  
concentration	  and	  the	  control	  being	  intermediate	  (Figure	  2).	  In	  
this	  case	  all	  the	  pairwise	  comparisons	  were	  significant	  (Table	  2	  
below)	  due	  to	  very	  low	  within-­‐treatment	  variance.	  
 
Fig	  2.	   Levels	   (mg	  dL-­‐1)	  of	   free	  cholesterol	   (x100),	  HDL/LDL	  cholesterol	  
and	   triglycerides	   in	   zebra	   fish	   liver	   after	   treatment	  with	  VY6.	   Results	  
are	   represented	   as	   average	   ±	   standard	   error	   of	   means.	   Different	  
letters	   (a,b,c)	   above	   bars	   of	   each	   lipid	   category	   refer	   to	   significant	  
differences	  among	  this	  lipid´s	  measured	  concentrations	  in	  response	  to	  
injection	  with	  nil,	  low,	  and	  high	  doses	  of	  VY-­‐6	  (P<0.01).	  
	  
Table	  1.	  Values	  of	  regression	  coefficients	  (R2),	  ranges	  tested	  for	  serial	  
standards	  used	  for	  metabolites	  calculations,	  and	  intraspecific	  errors	  
among	  duplicates	  of	  samples.	  
	  
	  
Lipids	   Treatment	  groups	  
Intraspecific	  
error	   R
2	   Linearity	  
range	  
Triglycerides	  
Control	   0.001	  
0.999	  
	  
Low	  dose	   0.002	   250-­‐0.4	  mg	  dL-­‐1	  
High	  dose	   0.003	   	  
Free	  
colesterol	  
Control	   0.001	  
0.999	  
	  
Low	  dose	   0.002	   250-­‐0.4	  mg	  dL-­‐1	  
High	  dose	   0.003	   	  
HDL	  
Control	   0.004	  
0.999	  
	  
Low	  dose	   0.005	   42-­‐0.34	  mg	  dL-­‐1	  
High	  dose	   0.004	   	  
	  
Table	   2.	   Pairwise	   Tukey’s	   test	   values	   for	   the	   differences	   between	  
experimental	   groups	   in	   average	   of	   lipid	   concentrations,	   below	  
diagonals.	  P-­‐values:	  above	  diagonals.	  
	  
Lipids	   Treatment	  
groups	  
Control	   Low	  dose	   High	  dose	  
	   Control	   -­‐	   0.0002	   0.007	  
Triglycerides	   Low	  dose	   17.22	   -­‐	   0.001	  
	   High	  dose	   6.721	   10.5	   -­‐	  
	   Control	   -­‐	   0.078	   0.185	  
Free	  
cholesterol	   Low	  dose	   3.839	   -­‐	   0.008	  
	   High	  dose	   2.879	   6.718	   -­‐	  
	   Control	   -­‐	   0.012	   0.012	  
HDL	   Low	  dose	   6.078	   -­‐	   0.0005	  
	   High	  dose	   6.078	   12.16	   -­‐	  
	  
 
C.3.	  RT-­‐PCR	  of	  acox1	  and	  lpl	  mRNA	  
	  
The	   intraperitoneal	   injection	   of	   zebra	   fish	   with	   the	   hexamer	  
peptide	  induced	  a	  dose-­‐dependent	   increase	  of	  the	  expression	  
of	  acox1	  and	  lpl	  genes,	  responsible	  for	  the	  degradation	  of	  fatty	  
acids	  and	  triglycerides,	  respectively	  (Figure	  3).	  
	  
	  	   	  
	  
Fig	   3.	   mRNA	   expression	   measured	   as	   mRNA	   levels	   of	   lpl	   and	   acox1	  
transcripts	   in	   relation	   to	   actb	   as	   reference	   gene.	   Above:	   the	   RT-­‐PCR	  
patterns	  for	  lpl	  (left)	  and	  acox1	  (right)	  3	  control,	  3	  low	  dose,	  and	  3	  high	  
dose	   samples.	   Results	   are	   represented	   as	   average	   ±	   standard	   error	  
(bars).	   Different	   letters	   (a,b)	   above	   bars	   of	   each	   gene	   refer	   to	  
significant	  differences	  among	  this	  gene´s	  measured	  expression	  in	  liver	  
in	  response	  to	  injection	  with	  nil,	  low,	  and	  high	  doses	  of	  VY-­‐6	  (P<0.01).	  
	  
The	   effect	   of	   the	   treatment	   was	   statistically	   significant	  
foracox1	   (one-­‐way	   ANOVA	   with	   F	   =	   13.11,	   P	   =	   0.002),	   and	  
marginally	   significant	   for	   lpl	   (one-­‐way	   ANOVA	   with	   F=	   4.065	  
and	   P=	   0.09).	   The	   dose-­‐dependent	   effect	   is	   reflected	   in	   the	  
second	  case	  in	  a	  significant	  difference	  between	  the	  control	  and	  
the	  group	  treated	  with	  the	  higher	  dose	  (Table	  3).	  
	  
Table	   3.	   Pairwise	   Tukey’s	   test	   values	   for	   the	   differences	   between	  
experimental	  group	  means	  of	  liver	  mRNA	  level	  of	   lpl	  (above	  diagonal)	  
and	  acox1	  (below	  diagonal)	  genes.	  Significant	  values	  are	  marked	  as	  **	  




Control	   Low	  dose	   High	  dose	  
Control	   -­‐	   2.173	   4.159	  **	  
Low	  dose	   0.642	   -­‐	   2.016	  




Zebra	  fish	  is	  considered	  a	  good	  model	  for	  metabolic	  assays	  of	  
different	   human	   foods,	   drinks,	   drugs	   and	   nutraceuticals	   in	  
general.	   For	   instance,	   it	   was	   used	   to	   test	   the	   efficiency	   of	  
human	   nutraceuticals-­‐delivering	   emulsions37,	   algal	  
polyphenols	   against	   stress38,	   developmental	   anomalies	  
resulting	   from	   inhibition	   of	   some	   essential	   mitochondrial	  
energy	   production	   cycles	   enzymes	   by	   human	   drugs39,	   green	  
tea	  as	  obesity	   inhibitor40,	  plant-­‐derived	  flavonoids	  as	  Taxifolin	  
against	   oxidative	   DNA	   damage41,	   probiotics	   and	   their	   effects	  
on	   the	   immune	   systems	  and	  also	   in	   reproduction42,43,	   as	  well	  
as	   many	   other,	   mostly	   human-­‐related,	   nutraceuticals	   and	  
drugs.	  
In	   the	   current	   trial,	   VY6	   peptide	   enhanced	   the	   levels	   of	   HDL	  
and	   reduced	   triglycerides	   efficiently.	   Enhancement	   also	   of	  
mRNA	   levels	   of	   lpl	   and	  acox1	   enzymes	   in	   the	   zebra	   fish,	   our	  
vertebrate	   experimental	   model,	   can	   refer	   to	   a	   positive	   role	  
that	   VY6	   plays	   as	   a	   nutraceutical,	   since	   these	   enzymes	   are	  
active	  participants	  in	  fatty	  acids	  degradation.	  It	  is	  the	  first	  time	  
to	   elucidate	   these	   physiological	   capabilities	   for	   the	   peptide	  
VY6,	   what	   makes	   them	   indeed	   interesting	   and	   novel	   results.	  
They	   strongly	   support	   the	   activity	   of	   VY6	   peptide	   on	   lipid	  
metabolism,	   and	   suggest	   this	   peptide	   may	   have	   an	   effect	   in	  
preventing	  or	  combating	  obesity	  in	  vertebrates.	  	  
More	   in	   detail,	  acox1	  mediates	   both	   fatty	   acids	   and	   reactive	  
oxygen	   species	   (ROS)	   metabolism	   in	   the	   peroxisomal	   β-­‐
oxidation	   process	   in	   liver	   and	   adipose	   tissues	   as	   the	   first	  
enzyme	   in	   this	  metabolic	   oxidation	   route3,4.	   Up-­‐regulation	   of	  
acox1	   gene	   expression	   correlates	   with	   obesity-­‐inhibitory	  
treatments	   in	   different	   experimental	   models.	   In	   general,	   its	  
enhancement	   is	   always	   concomitant	   to	   anti-­‐lipid	   deposition	  
effects	  in	  almost	  all	  levels	  of	  vertebrates,	  yet	  we	  were	  the	  first	  
to	   demonstrate	   it	   in	   zebra	   fish	   in	   response	   to	   β-­‐lg-­‐derived	  
peptide	   VY6.	   For	   examples,	   acox1	   enhanced	   upon	   feeding	  
mice	   on	   high	   fat	   diet	   mixed	   with	   concentrate	   of	   n-­‐3	  
polyunsaturated	   fatty	   acids	   from	   fish	   oil,	  what	   eventually	   led	  
to	   obesity	   reduction44.	   Moreover,	   acox1	   enhanced	   together	  
with	   body	   fat	   reduction	   in	   obese	   zebra	   fish	   given	   green	   tea	  
extract5,6.	   Broiler	   chickens	   given	   basal	   diet	   mixed	   with	  
dehydroepiandrosterone	   (DHEA)	   shown	   enhance	   acox1	  
levels45.	   Likewise,	   lpl	   is	   a	   potent	   controller	   for	   lipids,	   chiefly	  
acting	   as	   rate-­‐limiting	   enzyme	   for	   the	   hydrolysis	   of	  
triglycerides	  and	  potent	  anti-­‐hypertriglyceridemia7.	  Our	  results	  
clearly	   demonstrated	   this	   anti-­‐hypertriglyceridemic	   effect,	  
with	   both	   concentrations	   tested	   of	   VY6	   showing	   significant	  
reduction	   in	   triglycerides.	   However,	   the	   more	   significant	  
enhancement	  of	  lpl	  by	  the	  high	  dose	  than	  by	  the	  low	  dose	  may	  
refer	   to	   VY6	   capability	   to	   stimulate	  more	   lpl	   synthesis	   at	   the	  
high	   dose.	   Adult	   liver	   in	   zebra	   fish	   is	   the	   organ	   where	  
maximum	  lpl	  expression	  can	  be	  found,	  in	  comparison	  to	  other	  
organs	   in	  the	  body46.	   Its	  expression	   in	   livers	   further	  enhances	  
upon	  feeding	  animals	  on	  high	  fat	  diets47,48.	  
Alongside	   with	   the	   increase	   of	   expression	   of	   the	   lipid-­‐
degrading	  enzyme	  genes,	  the	  anti-­‐obesity	  effect	  of	  the	  assayed	  
peptide	   is	   clearly	   revealed	   by	   significantly	   lower	   levels	   of	  
hepatic	  ¨bad¨	  cholesterol	  and	  significantly	  higher	  levels	  of	  the	  
¨good	  cholesterol¨	  HDL.	  However,	   it	   seems	  that	   the	   low	  dose	  
of	   the	  VY6	  showed	  better	  overall	   results	   for	   lipids	   levels	   than	  
the	   higher	   dose.	   For	   the	   insignificance	   of	   both	   acox1	   and	   lpl	  
increase	  in	  response	  to	  the	  low	  dose	  of	  VY6,	  it	  should	  be	  taken	  
into	   account	   that	   enzymes´	   mRNA	   synthesis	   is	   often	  
dependent	   upon	   the	   available	   quantity	   of	   the	   enzymes´	  
proteins.	   This	   means	   that	   if	   there	   is	   a	   high	   level	   of	   enzyme	  
protein	  quantity	  and	  activity,	  the	  need	  for	  mRNA	  transcription	  
for	   production	   of	  more	   enzyme	   units	   diminishes.	  We	   believe	  
that	  this	  is	  the	  explanation	  of	  our	  case	  since	  ¨bad¨	  lipids	  levels	  
were	  much	   lower	   in	  response	  to	  VY-­‐6	   low	  dose	  than	  the	  high	  
dose.	   Both	   lpl	   and	   acox1	   activities	   are	   governed	   via	  
posttranslational	   mechanisms	   and	   the	   discrepancy	   for	   their	  
mRNAs/proteins	  levels	  is	  known49,50,51.	  
The	  VY6	  peptide	  could	  be	  used	  as	  a	  nutraceutical	   if	   its	  effects	  
on	   lipid	   metabolism	   are	   confirmed	   with	   further	   experiments	  
with	   some	   mammalian	   models	   and	   even	   possibly	   with	  
volunteers.	  Now	  it	  is	  known	  that	  animal	  and	  plant	  proteins	  are	  
active	   source	   of	   nutraceuticals,	   which	   is	   a	   role	   extending	   far	  
beyond	   their	   traditional	   role	   in	   nutrition.	   Food-­‐derived	  
peptides	   exhibit	   antimicrobial	   properties,	   blood	   pressure-­‐
lowering	   effects,	   cholesterol-­‐lowering	   ability,	   antithrombotic	  
and	   antioxidant	   activities,	   enhancement	   of	  
immunomodulatory	   effects,	   inhibit	   cancer	   cell	   growth,	  
enhance	   mineral	   uptake,	   diabetes,	   obesity,	   obesity-­‐induced	  
inflammation	   and	   exhibit	   potent	   opioid	   activities52,53,54.	   They	  
can	   be	   effectively	   used	   then	   to	   reduce	   risk	   of	   disease	   or	   to	  
enhance	  certain	  physiological	  functions.	  	  
	   	  
	   	  
Conclusions	  
The	  peptide	  VY6	  derived	   from	  β-­‐lg	  exhibited	  positive	   impacts	  
on	   lipid	   deposition	   in	   the	   zebra	   fish	   liver.	   This,	   besides	   other	  
previously	   demonstrated	   functions	   of	   that	   peptide,	  
recommends	   VY6	   as	   a	   promising,	   milk-­‐derived	   nutraceutical	  
that	   may	   exhibit	   positive	   effects	   against	   obesity	   and	   DPP-­‐IV	  
production.	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